Market Research Report
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
|Published by||La Merie Publishing||Product code||327820|
|Published||Content info||462 Pages
|Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update|
|Published: May 25, 2016||Content info: 462 Pages||
This Competitive Intelligence report about ‘Biosimilar & Biosuperior Therapeutic Antibodies’ updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.
The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.
The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.
Competitor projects are listed in a tabular format providing information on:
Blockbuster Therapeutic Antibodies in 2015
(by generic name)